- CONSORT Statement
- CONSORT Statement Extensions
- Evidence underpinning CONSORT
- Accrual and sample size
- Attitudes to trials
- Adverse events (Harms)
- Baseline data
- Blinding
- Compliance
- Early stopping
- Eligibility
- Follow-up
- Funding
- Harms
- Generalizability
- Intention to treat
- Interpretation
- Interventions
- Outcome reporting
- Random allocation
- Recruitment
- Statistical analysis
- Statistical methods
- Trial design issues
- Trial registration
- Uptake of CONSORT by journals
- Impact of and adherence to CONSORT
- Endorsement of CONSORT
Funding
Als-Nielsen B,
Chen W, Gluud C, Kjaergard LL. Association of funding
and conclusions in randomized drug trials: a reflection of treatment effect or
adverse events? JAMA 2003; 290(7):921-928.
PMID: 12928469
Barden J, Derry S, Mcquay HJ, Moore RA. Bias from industry
trial funding? A framework, a suggested approach, and a negative result. Pain
2006; 121(3):207-218.
PMID: 16495012
Bekelman JE, Li Y, Gross CP. Scope and impact of financial
conflicts of interest in biomedical research: a systematic review. JAMA 2003;
289(4):454-465.
PMID: 12533125
Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated
with findings of published trials of drug-drug comparisons: why some statins
appear more efficacious than others. PLoS Med 2007; 4(6):e184.
PMID: 17550302
Bero LA, Rennie D. Influences on the quality of published
drug studies. Int J Technol Assess Health Care 1996; 12(2):209-237.
PMID: 8707496
Brown A, Kraft D, Schmitz SM, Sharpless V, Martin C, Shah
R, Shaheen NJ. Association of industry sponsorship to published outcomes in
gastrointestinal clinical research. Clin Gastroenterol Hepatol 2006; 4(12):1445-1451.
PMID: 17101295
Chalmers I, Rounding C, Lock K. Descriptive survey of
non-commercial randomised controlled trials in the United Kingdom, 1980-2002.
BMJ 2003; 327(7422):1017.
PMID: 14593034
Clifford TJ, Moher D, Barrowman N. Absence of associations between funding source, trial outcome, and quality score: a benefit of financial disclosure? 4th International Congress on Peer Review in Biomedical Publication, September 14 16, 2001 in Barcelona, Spain 2001.
Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, Kotzin S, Nicholls MG, Nylenna M, Overbeke AJ, Sox HC, Van Der Weyden MB, Wilkes MS. Sponsorship, authorship, and accountability. JAMA 2001; 286(10):1232-1234.
PMID: 11559271 [New]
DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: the adverse effects of industry influence. JAMA 2008; 299(15):1833-1835.
PMID: 18413880 [New]
Decullier E, Chapuis F. Impact of funding on biomedical
research: a retrospective cohort study. BMC Public Health 2006; 6:165.
PMID: 16792794
Etter JF, Burri M, Stapleton J. The impact of
pharmaceutical company funding on results of randomized trials of nicotine
replacement therapy for smoking cessation: a meta-analysis. Addiction 2007;
102(5):815-822.
PMID: 17493109
Gøtzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman
DG, Chan AW. Constraints on publication rights in industry-initiated clinical
trials. JAMA 2006; 295(14):1645-1646.
PMID: 16609085
Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews
compared with industry supported meta-analyses and other meta-analyses of the
same drugs: systematic review. BMJ 2006; 333(7572):782.
PMID: 17028106
Kjaergard LL, Gluud C. Funding, disease area, and internal
validity of hepatobiliary randomized clinical trials. Am J Gastroenterol 2002; 97(11):2708-2713.
PMID: 12425537
Lesser LI, Ebbeling CB, Goozner
M, Wypij D, Ludwig DS. Relationship between funding
source and conclusion among nutrition-related scientific articles. PLoS Med
2007; 4(1):e5.
PMID: 17214504
Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical
industry sponsorship and research outcome and quality: systematic review. BMJ
2003; 326(7400):1167-1170.
PMID: 12775614
Liss H. Publication bias in the pulmonary/allergy
literature: effect of pharmaceutical company sponsorship. Isr Med Assoc J 2006;
8(7):451-454.
PMID: 16889157
Melander H, hlqvist-Rastad J, Meijer G, Beermann B.
Evidence b(i)ased medicine--selective reporting from studies sponsored by
pharmaceutical industry: review of studies in new drug applications. BMJ 2003;
326(7400):1171-1173.
PMID: 12775615
Moja PL, Moschetti I, D'Amico R. Outcome reporting bias in
government-funded RCTs. CMAJ 2005; 172(7):857.
PMID: 15795393
Montgomery JH, Byerly M, Carmody T, Li B, Miller DR,
Varghese F, Holland R. An analysis of the effect of funding source in
randomized clinical trials of second generation antipsychotics for the
treatment of schizophrenia. Control Clin Trials 2004; 25(6):598-612.
PMID: 15588746
Perlis RH, Perlis CS, Wu Y, Hwang
C, Joseph M, Nierenberg AA. Industry sponsorship and
financial conflict of interest in the reporting of clinical trials in
psychiatry. Am J Psychiatry 2005; 162(10):1957-1960.
PMID: 16199844
Ridker PM, Torres J. Reported outcomes in major
cardiovascular clinical trials funded by for-profit and not-for-profit
organizations: 2000-2005. JAMA 2006; 295(19):2270-2274.
PMID: 16705108
Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008; 299(15):1800-1812.
PMID: 18413874 [New]
Safer DJ. Design and reporting modifications in
industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002;
190(9):583-592.
PMID: 12357091
Scharf O, Colevas AD. Adverse event reporting in
publications compared with sponsor database for cancer clinical trials. J Clin
Oncol 2006; 24(24):3933-3938.
PMID: 16921045
Shah RV, Albert TJ, Bruegel-Sanchez V, Vaccaro AR,
Hilibrand AS, Grauer JN. Industry support and correlation to study outcome for
papers published in Spine. Spine 2005; 30(9):1099-1104.
PMID: 15864166
Thomas O, Thabane L, Douketis J, Chu R, Westfall AO, Allison DB. Industry funding and the reporting quality of large long-term weight loss trials. Int J Obes (Lond) 2008;
PMID: 18711388 [New]
Tuech JJ, Moutel G, Pessaux P, Thoma V, Schraub S, Herve C.
Disclosure of competing financial interests and role of sponsors in phase III
cancer trials. Eur J Cancer 2005; 41(15):2237-2240.
PMID: 16214044
Tulikangas PK, Ayers A, O'Sullivan DM. A meta-analysis
comparing trials of antimuscarinic medications funded by industry or not. BJU
Int 2006; 98(2):377-380.
PMID: 16879680
Wahlbeck K, Adams C. Beyond conflict of interest. Sponsored
drug trials show more-favourable outcomes. BMJ 1999; 318(7181):465.
PMID: 10084842
Yaphe J, Edman R, Knishkowy B, Herman J. The association
between funding by commercial interests and study outcome in randomized
controlled drug trials. Fam Pract 2001; 18(6):565-568.
PMID: 11739337
Page last edited: 06 May 2009
